Objective: The present study assesses whether phosphodiesterase type 5 (PDE-5) inhibitor or carnitine exert nephroprotective effects against clinical contrast-induced nephropathy (CIN). The gene discussed is PDE5A; the disease is cervical squamous intraepithelial neoplasia.